Welcome to our dedicated page for Exponent SEC filings (Ticker: EXPO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The EXPO SEC filings page on Stock Titan provides access to Exponent, Inc.’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed science and engineering consulting firm, Exponent uses SEC reports to present detailed information about its financial condition, operating performance, and material events. These filings complement the company’s earnings releases and offer structured data on revenues before reimbursements, operating expenses, segment performance, and non-GAAP measures such as EBITDA and EBITDAS.
Investors can use this page to locate Exponent’s periodic reports, including annual and quarterly filings that discuss its two operating segments: the engineering and other scientific segment and the environmental and health segment. These documents describe how much each segment contributes to revenues before reimbursements and provide narrative explanations of demand trends in areas such as dispute-related services, risk management projects, and regulatory consulting across industries like construction, automotive, medical devices, utilities, chemicals, transportation, and life sciences.
The EXPO filings page also highlights current reports on Form 8-K, where Exponent discloses material events. Recent 8-K filings have incorporated press releases announcing quarterly financial results, dividend declarations, and changes to share repurchase authorizations. These filings give timely insight into board decisions on capital returns and into management’s assessment of market conditions and business performance.
Stock Titan enhances access to these documents with AI-powered summaries that explain key sections in plain language, helping readers interpret complex accounting and technical terminology. Users can quickly see how Exponent’s reported metrics, segment data, and capital allocation actions fit into its broader consulting business. This makes the EXPO SEC filings page a useful starting point for understanding Exponent’s regulatory history and ongoing reporting as a professional, scientific, and technical services company.
Exponent Inc. President & CEO Catherine Corrigan reported routine equity compensation activity. On March 11, 2026, she exercised vested Restricted Stock Units covering 12,716 shares of common stock on a 1:1 basis, converting them into 12,716 shares of common stock at a stated price of $0.00 per share.
To satisfy tax withholding obligations tied to this vesting, 6,156 common shares were withheld by the company at a reference price of $70.03 per share, according to the filing footnotes. After these transactions, Corrigan directly holds 100,969 shares of Exponent common stock. This filing reflects compensation-related vesting and associated tax withholding, not an open-market purchase or sale.
Exponent Inc. Group Vice President Maureen T. F. Reitman reported a bona fide gift of 140 shares of Exponent common stock. The gift was recorded at a price of $0.00 per share and is classified as a disposition by gift, not an open-market sale. After this transaction, she directly owns 35,472 shares of Exponent common stock.
Exponent, Inc. is a science and engineering consulting firm that helps clients analyze failures, manage risk, and develop products across more than 90 technical disciplines. It operates two segments, Engineering and Other Scientific and Environmental and Health, with 17 specialized practices ranging from biomechanics and data sciences to chemical regulation and health sciences.
Clients span industries such as consumer products, energy, transportation, and chemicals, which represented about 21%, 20%, 16% and 11% of 2025 revenues. Work is typically project-based and billed hourly at professional rates from $225 to $1,375. As of January 2, 2026, the company employed 1,212 people, including 949 technical staff and 731 with doctorates.
The aggregate market value of common stock held by non‑affiliates was approximately $3.0 billion as of July 4, 2025, and 49,254,339 shares were outstanding as of February 20, 2026. Key risks include volatile, event‑driven demand, competition, reliance on highly skilled personnel, regulatory and tort changes, cybersecurity and data privacy threats, rapid developments in artificial intelligence, international and macroeconomic uncertainty, and potential climate‑related and catastrophic disruptions.
Corrigan Catherine reported acquisition or exercise transactions in this Form 4 filing.
Exponent Inc. President and CEO Catherine Corrigan reported awards of stock options, increasing her potential equity exposure to the company. She received 1,425 Incentive Stock Options and 27,075 Non-Qualified Stock Options, both granted at no cost as part of her compensation.
According to the disclosure, each stock option grant becomes exercisable in four equal annual installments, meaning the rights vest gradually over four years rather than all at once. These are options giving her the right to buy shares in the future; they are not immediate stock purchases or sales.
SCHLENKER RICHARD L JR reported acquisition or exercise transactions in this Form 4 filing.
Exponent Inc EVP & CFO Richard L. Schlenker Jr. reported awards of stock options on February 20, 2026. He received 1,425 incentive stock options and 17,575 non-qualified stock options, each representing rights to buy Exponent shares. According to the footnotes, these options become exercisable in four equal annual installments.
Exponent Inc. President & CEO Catherine Corrigan exercised two non-qualified stock options, acquiring 3,226 and 2,380 shares of common stock at exercise prices of $25.4050 and $29.0500. She then sold a total of 3,920 shares of common stock, including 2,218 shares at $67.1646 and 1,702 shares at $67.1378, with the stock sale used to cover the option exercise price and taxes as noted in the footnotes.
Exponent Inc. insider Catherine Corrigan has filed a Form 144 notice to sell shares of EXPO common stock. The filing covers a planned sale of 3,920 common shares through Morgan Stanley Smith Barney LLC on or about 02/17/2026, with an aggregate market value of $261,816.80. The shares were acquired the same day by exercising stock options for cash.
The notice also reports prior Rule 10b5-1 plan sales over the past three months. These include 1,663 common shares sold on 01/15/2026 for gross proceeds of $120,593.78 and 3,225 common shares sold on 12/15/2025 for $240,171.23. Shares outstanding were 49,887,226 at the time referenced, providing context for the size of these trades.
Exponent Inc.'s Executive Vice President and Chief Financial Officer, Richard L. Schlenker Jr., reported an option exercise that increased his direct common stock holdings. On February 11, 2026, he exercised an Incentive Stock Option for 4,230 shares at an exercise price of $23.63 per share, converting the derivative position into common stock. Following this transaction, he directly owned 226,109 shares of Exponent common stock.
Exponent Inc.'s VP Global Offices & Innovation, John Pye, reported selling a total of 4,000 shares of common stock in open-market transactions on February 10, 2026. The sales occurred in two trades: 341 shares at $75.935 and 3,659 shares at $75.9781 per share.
Following these sales, Pye directly owns 25,204 shares of Exponent common stock. All reported holdings are listed as directly owned, with no indirect ownership disclosed in this filing.
A shareholder of EXPO has filed a notice of intent to sell 4,000 shares of common stock, with an aggregate market value of $303,897.70. The shares are listed as trading on NASDAQ, and the issuer reports 49,887,226 common shares outstanding at the time of the notice.
The filing details that the shares to be sold were acquired over several years through an employee stock purchase plan and restricted stock awards, with acquisition dates ranging from 2016 to 2025. The filer represents that they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations.